Seclidemstat (mesylate)

Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM) . Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma[1][2].

Product Specifications

CAS Number

[2044953-70-8]

Product Name Alternative

SP-2577 (mesylate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Demethylase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/seclidemstat-mesylate.html

Purity

99.80

Solubility

DMSO : 53.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N/N=C(C1=CC(Cl)=CC=C1O)\C)C2=CC=CC(S(=O)(N3CCN(C)CC3)=O)=C2.CS(O)(=O)=O

Molecular Formula

C21H27ClN4O7S2

Molecular Weight

547.04

Precautions

H302, H315, H319, H335

References & Citations

[1]Dai XJ, et al. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [published correction appears in J Med Chem. 2021 May 13;64 (9) :6410-6411]. J Med Chem. 2021;64 (5) :2466-2488. |[2]Soldi R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One. 2020;15 (7) :e0235705. Published 2020 Jul 10.